{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:35:21Z","timestamp":1792607721810,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ejca.2025.115451","type":"journal-article","created":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T11:10:03Z","timestamp":1745061003000},"page":"115451","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Going beyond the 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting"],"prefix":"10.1016","volume":"222","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9379-5938","authenticated-orcid":false,"given":"Karin","family":"Jordan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9501-4509","authenticated-orcid":false,"given":"Evandro","family":"de Azambuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda \u00c1ngeles","family":"Garc\u00eda del Barrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Jahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8639-1898","authenticated-orcid":false,"given":"Mario","family":"Di Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Scott\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Molassiotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti","family":"Aapro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2025.115451_bib1","first-page":"5","article-title":"CINV: still troubling patients after all these years","volume":"26","author":"Aapro","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ejca.2025.115451_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102195","article-title":"2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting","volume":"9","author":"Herrstedt","year":"2024","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.ejca.2025.115451_bib3","first-page":"53","article-title":"Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents-updated MASCC\/ESMO consensus recommendation","volume":"32","author":"Jordan","year":"2023","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ejca.2025.115451_bib4","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.3390\/cancers14041022","article-title":"Emetogenicity of antibody-drug conjugates (ADCs) in solid tumors with a focus on trastuzumab deruxtecan: insights from an italian expert panel","volume":"14","author":"Bianchini","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2025.115451_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100553","article-title":"Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer","volume":"7","author":"Rugo","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2025.115451_bib6","author":"Sakai","year":"2024","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2025.115451_bib7","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jpainsymman.2013.06.012","article-title":"Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study","volume":"47","author":"Molassiotis","year":"2014","journal-title":"J Pain Symptom Manag"},{"key":"10.1016\/j.ejca.2025.115451_bib8","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/annonc\/mdx100","article-title":"The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting","volume":"28","author":"Dranitsaris","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115451_bib9","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1093\/annonc\/mds021","article-title":"The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)","volume":"23","author":"Aapro","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115451_bib10","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejca.2022.01.028","article-title":"Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea and vomiting: results of the nausea\/emesis registry in oncology (NERO)","volume":"166","author":"Aapro","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115451_bib11","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/sj.bjc.6603048","article-title":"Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy","volume":"94","author":"Vardy","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2025.115451_bib12","first-page":"70","article-title":"Retrospective review of the incidence of monitoring blood glucose levels in patients receiving corticosteroids with systemic anticancer therapy","volume":"4","author":"Rowbottom","year":"2015","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.ejca.2025.115451_bib13","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/annonc\/mdp584","article-title":"Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy","volume":"21","author":"Aapro","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115451_bib14","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1200\/JCO.2017.74.4375","article-title":"Placebo-controlled, double-blinded phase III study comparing dexamethasone on day 1 with dexamethasone on days 1 to 3 With combined neurokinin-1 receptor antagonist and palonosetron in high-emetogenic chemotherapy","volume":"36","author":"Ito","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115451_bib15","doi-asserted-by":"crossref","first-page":"e1854","DOI":"10.1002\/onco.13851","article-title":"Dexamethasone-sparing regimens with oral netupitant and palonosetron for the prevention of emesis caused by high-dose cisplatin: a randomized noninferiority study","volume":"26","author":"Celio","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2025.115451_bib16","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.2217\/fon-2022-0330","article-title":"Efficacy of the dexamethasone-sparing triplet regimen for preventing cisplatin-induced emesis: a combined analysis","volume":"18","author":"Celio","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.ejca.2025.115451_bib17","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.breast.2020.11.002","article-title":"A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting","volume":"54","author":"Clemons","year":"2020","journal-title":"Breast"},{"key":"10.1016\/j.ejca.2025.115451_bib18","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","article-title":"Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Hashimoto","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115451_bib19","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00432-024-05712-7","article-title":"A prospective randomized controlled clinical trial investigating the efficacy of low-dose olanzapine in preventing nausea and vomiting associated with oxaliplatin-based and irinotecan-based chemotherapy","volume":"150","author":"Shen","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115451_bib20","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1470-2045(23)00628-9","volume":"25","author":"Bajpai","year":"2024","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2025.115451_bib21","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1007\/s10147-024-02603-2","article-title":"Comparison of olanzapine 2.5 mg and 5 mg in the prevention of chemotherapy-induced nausea and vomiting: a Japanese nationwide database study","volume":"29","author":"Suzuki-Chiba","year":"2024","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115451_bib22","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/oncolo\/oyac240","article-title":"Duration of chemotherapy-induced nausea and vomiting (CINV) as a predictor of recurrent CINV in later cycles","volume":"28","author":"Navari","year":"2023","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.ejca.2025.115451_bib23","first-page":"2759","article-title":"Development and preliminary validation of a risk prediction model for chemotherapy-related nausea and vomiting","volume":"21","author":"Molassiotis","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ejca.2025.115451_bib24","doi-asserted-by":"crossref","DOI":"10.2196\/27024","article-title":"A Smartphone-based decision support tool for predicting patients at risk of chemotherapy-induced nausea and vomiting: retrospective study on app development using decision tree induction","volume":"9","author":"Mosa","year":"2021","journal-title":"JMIR Mhealth Uhealth"},{"key":"10.1016\/j.ejca.2025.115451_bib25","doi-asserted-by":"crossref","first-page":"18306","DOI":"10.1002\/cam4.6428","article-title":"A deep learning-based interpretable decision tool for predicting high risk of chemotherapy-induced nausea and vomiting in cancer patients prescribed highly emetogenic chemotherapy","volume":"12","author":"Zhang","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2025.115451_bib26","article-title":"NEPA versus standard of care for CINV prevention in patients at increased emetic risk receiving moderately emetogenic chemotherapy","author":"Molassiotis","year":"2023","journal-title":"Presented at MASCC\/JASCC\/ISOO Annual Meeting 22-24 June"},{"key":"10.1016\/j.ejca.2025.115451_bib27","first-page":"672","article-title":"Effectiveness of e-health interventions for chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis","volume":"32","author":"Zhang","year":"2024","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ejca.2025.115451_bib28","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.clbc.2024.04.003","article-title":"Gastrointestinal toxicity of antibody drug conjugates (ADCs) in metastatic breast cancer: a pooled analysis","volume":"24","author":"Pedersini","year":"2024","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ejca.2025.115451_bib29","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines - Antiemesis, version 2. NCCN 2024."},{"issue":"1","key":"10.1016\/j.ejca.2025.115451_bib30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.annonc.2024.10.017","article-title":"Beyond the usual window: persistent nausea with trastuzumab deruxtecan calls for new management strategies","volume":"36","author":"Jordan","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115451_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1374547","article-title":"Management of Trastuzumab Deruxtecan-related nausea and vomiting in real-world practice","volume":"14","author":"Notini","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2025.115451_bib32","first-page":"3441","article-title":"Reality of the emetogenic level of irinotecan","volume":"26","author":"Garcia Del Barrio","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ejca.2025.115451_bib33","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.26076","article-title":"Olanzapine as antiemetic prophylaxis in moderately emetogenic chemotherapy: a phase 3 randomized clinical trial","volume":"7","author":"Ostwal","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"12","key":"10.1016\/j.ejca.2025.115451_bib34","first-page":"657","article-title":"Efficacy and safety of 5HT3RA, DEX, and NK1RA for the prevention of FOLFIRINOX-induced nausea and vomiting in patients with pancreatic cancer: a retrospective cohort study","volume":"31","author":"Hishida-Sadaka","year":"2023","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ejca.2025.115451_bib35","first-page":"382","article-title":"The prevention and treatment of nausea and vomiting during tumor therapy","volume":"119","author":"Jahn","year":"2022","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.ejca.2025.115451_bib36","doi-asserted-by":"crossref","first-page":"705866","DOI":"10.3389\/fonc.2021.705866","article-title":"The Balance Between the Effectiveness and Safety for Chemotherapy-Induced Nausea and Vomiting of Different Doses of Olanzapine (10 mg Versus 5 mg): a Systematic Review and Meta-Analysis","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2025.115451_bib37","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.annonc.2020.07.020","article-title":"Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial","volume":"31","author":"Grimison","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115451_bib38","first-page":"JCO2301836","article-title":"Oral cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: final results of a randomized, placebo-controlled, phase II\/III Trial","author":"Grimison","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115451_bib39","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.annonc.2020.08.2104","article-title":"Cannabinoids as antiemetics: everything that\u2019s old is new again","volume":"31","author":"Warr","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115451_bib40","doi-asserted-by":"crossref","first-page":"565","DOI":"10.23736\/S0375-9393.22.16983-X","article-title":"The efficacy of 5HT3-receptor antagonists in postoperative nausea and vomiting: the role of pharmacogenetics","volume":"89","author":"Theodosopoulou","year":"2023","journal-title":"Minerva Anestesiol"},{"key":"10.1016\/j.ejca.2025.115451_bib41","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1634\/theoncologist.12-9-1151","article-title":"Randomized crossover pharmacokinetic evaluation of subcutaneous versus intravenous granisetron in cancer patients treated with platinum-based chemotherapy","volume":"12","author":"Gurpide","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2025.115451_bib42","first-page":"133","article-title":"Granisetron extended-release subcutaneous injection versus palonosetron infusion for CINV prevention: cost comparison of unscheduled hydration","volume":"14","author":"Barnes","year":"2021","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.ejca.2025.115451_bib43","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/annonc\/mdx698","volume":"29","author":"Zhang","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115451_bib44","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.2217\/fon-2021-0023","article-title":"Single-dose netupitant\/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis","volume":"17","author":"Navari","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.ejca.2025.115451_bib45","doi-asserted-by":"crossref","first-page":"e1870","DOI":"10.1002\/onco.13888","article-title":"A pragmatic study evaluating NEPA versus aprepitant for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy","volume":"26","author":"Zelek","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2025.115451_bib46","doi-asserted-by":"crossref","first-page":"15769","DOI":"10.1002\/cam4.6121","article-title":"Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy","volume":"12","author":"Zelek","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2025.115451_bib47","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/00000421-199504000-00017","article-title":"Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial","volume":"18","author":"Malik","year":"1995","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115451_bib48","first-page":"1533","article-title":"Anticipatory nausea and vomiting","volume":"19","author":"Roscoe","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ejca.2025.115451_bib49","first-page":"112","article-title":"Effect of lorazepam in reducing psychological distress and anticipatory nausea and vomiting in patients undergoing chemotherapy","volume":"8","author":"James","year":"2017","journal-title":"J Pharm Pharm"},{"key":"10.1016\/j.ejca.2025.115451_bib50","first-page":"30","article-title":"2023 MASCC\/ESMO consensus antiemetic guidelines related to integrative and non-pharmacological therapies","volume":"32","author":"Molassiotis","year":"2023","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ejca.2025.115451_bib51","first-page":"505","article-title":"Prevalence and predictors of long-delayed (>\u202f120h) chemotherapy-induced nausea and vomiting (CINV)-a systematic review and individual patient data meta-analysis","volume":"31","author":"Chow","year":"2023","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ejca.2025.115451_bib52","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.7150\/jca.87169","article-title":"Doublet or triplet antiemetic prophylaxis for nausea and vomiting induced by trastuzumab deruxtecan: an open-label, randomized, and multicenter exploratory phase 2 study","volume":"14","author":"Iihara","year":"2023","journal-title":"J Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925002321?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925002321?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:35:08Z","timestamp":1762342508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925002321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":52,"alternative-id":["S0959804925002321"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115451","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Going beyond the 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115451","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115451"}}